Abstract
Thirty percent of males afflicted with erectile dysfunction (ED) do not respond to oral drugs, another 15% reveal contraindications to currently available therapy, and a subset of patients actually prefer injection therapy due to its predictable short time-to-onset of erection and reliable rigidity compared to oral drugs. This paper provides both a historical and current perspective on intracavernosal therapy and reviews the popular injectable therapeutic agents that are currently used for the treatment of ED. Emphasis is placed on the efficacy, mechanism of action and side effect profiles of approved and experimental injectable pharmacotherapy for ED.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Porst, H. Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Int J Impot Res 12 (Suppl 4), S91–S100 (2000). https://doi.org/10.1038/sj.ijir.3900585
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3900585
Keywords
This article is cited by
-
Delivery of intracavernosal therapies using needle-free injection devices
International Journal of Impotence Research (2017)
-
Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders
International Journal of Impotence Research (2005)
-
Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances
International Journal of Impotence Research (2004)
-
New achievements and pharmacotherapeutic approaches to impotence in the elderly
Aging Clinical and Experimental Research (2003)
-
The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial
International Journal of Impotence Research (2001)